CoChat
Sign Up
Cited by 19

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Human papillomavirus oncoproteins and post-translational modifications: generating multifunctional hubs for overriding cellular homeostasis

Basukala, Om, Sarabia-Vega, Vanessa, Banks, Lawrence·2020·Biological Chemistry
DOI 10.1515/hsz-2019-0408
Open this paper in CoChat — free account

Abstract

Human papillomaviruses (HPVs) are major human carcinogens, causing around 5% of all human cancers, with cervical cancer being the most important. These tumors are all driven by the two HPV oncoproteins E6 and E7. Whilst their mechanisms of action are becoming increasingly clear through their abilities to target essential cellular tumor suppressor and growth control pathways, the roles that post-translational modifications (PTMs) of E6 and E7 play in the regulation of these activities remain unclear. Here, we discuss the direct consequences of some of the most common PTMs of E6 and E7, and how this impacts upon the multi-functionality of these viral proteins, and thereby contribute to the viral life cycle and to the induction of malignancy. Furthermore, it is becoming increasingly clear that these modifications, may, in some cases, offer novel routes for therapeutic intervention in HPV-induced disease.

Overview

Integrity signals

Registry

Crossref · 10.1515/hsz-2019-0408

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 119

  1. Ackerman, P. and Osheroff, N. (1989). Regulation of casein kinase II activity by epidermal growth factor in human A-431 carcinoma cells. J. Biol. Chem. 264, 11958–11965. · DOI
  2. Armstrong, D.J. and Roman, A. (1995). Human papillomavirus type 6 E7 protein is a substrate in vitro of protein kinase C. Biochem. J. 312, 667–670. · DOI
  3. Banks, L., Pim, D., and Thomas, M. (2003). Viruses and the 26S proteasome: hacking into destruction. Trends Biochem. Sci. 28, 452–459. · DOI
  4. Barbosa, M.S., Edmonds, C., Fisher, C., Schiller, J.T., Lowy, D.R., and Vousden, K.H. (1990). The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J. 9, 153–160. · DOI
  5. Barnard, D., Diaz, H.B., Burke, T., Donoho, G., Beckmann, R., Jones, B., Barda, D., King, C., and Marshall, M. (2016). LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models. Invest. New Drugs 34, 49–60. · DOI
  6. Basukala, O., Mittal, S., Massimi, P., Bestagno, M., and Banks, L. (2019). The HPV-18 E7 CKII phospho acceptor site is required for maintaining the transformed phenotype of cervical tumour-derived cells. PLoS Pathog. 15, e1007769. · DOI · Paper page
  7. Bazzo Goulart, K.O., Guerra Godoy, A.E., Litvin, I.E., and Firmbach Pasqualotto, F. (2017). Expression analysis of transglutaminase 2 in premalignant lesions of the cervix. Appl. Cancer Res. 37, 27. · DOI
  8. Ben-Saadon, R., Fajerman, I., Ziv, T., Hellman, U., Schwartz, A.L., and Ciechanover, A. (2004). The tumor suppressor protein p16(INK4a) and the human papillomavirus oncoprotein-58 E7 are naturally occurring lysine-less proteins that are degraded by the ubiquitin system. Direct evidence for ubiquitination at the N-terminal residue. J. Biol. Chem. 279, 41414–41421. · DOI
  9. Berezutskaya, E. and Bagchi, S. (1997). The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome. J. Biol. Chem. 272, 30135–30140. · DOI
  10. Bodily, J.M., Mehta, K.P., Cruz, L., Meyers, C., and Laimins, L.A. (2011). The E7 open reading frame acts in cis and in trans to mediate differentiation-dependent activities in the human papillomavirus type 16 life cycle. J. Virol. 85, 8852–8862. · DOI
  11. Boon, S.S. and Banks, L. (2013). High-risk human papillomavirus E6 oncoproteins interact with 14-3-3zeta in a PDZ binding motif-dependent manner. J. Virol. 87, 1586–1595. · DOI
  12. Boon, S.S., Tomaic, V., Thomas, M., Roberts, S., and Banks, L. (2015). Cancer-causing human papillomavirus E6 proteins display major differences in the phospho-regulation of their PDZ interactions. J. Virol. 89, 1579–1586. · DOI
  13. Butz, K., Ristriani, T., Hengstermann, A., Denk, C., Scheffner, M., and Hoppe-Seyler, F. (2003). siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22, 5938–5945. · DOI · Paper page
  14. Calcada, E.O., Felli, I.C., Hosek, T., and Pierattelli, R. (2013). The heterogeneous structural behavior of E7 from HPV16 revealed by NMR spectroscopy. ChemBioChem 14, 1876–1882. · DOI
  15. Chemes, L.B., Sanchez, I.E., Smal, C., and de Prat-Gay, G. (2010). Targeting mechanism of the retinoblastoma tumor suppressor by a prototypical viral oncoprotein. Structural modularity, intrinsic disorder and phosphorylation of human papillomavirus E7. FEBS J. 277, 973–988. · DOI
  16. Chen, J. (2015). Signaling pathways in HPV-associated cancers and therapeutic implications. Rev. Med. Virol. 25 (Suppl 1), 24–53. · DOI
  17. Chin, C., Bae, J.H., Kim, M.J., Hwang, J.Y., Kim, S.J., Yoon, M.S., Lee, M.K., Kim, D.W., Chung, B.S., Kang, C.D., et al. (2005). Radiosensitization by targeting radioresistance-related genes with protein kinase A inhibitor in radioresistant cancer cells. Exp. Mol. Med. 37, 608–618. · DOI
  18. Cho-Chung, Y.S. and Nesterova, M.V. (2005). Tumor reversion: protein kinase A isozyme switching. Ann. N. Y. Acad. Sci. 1058, 76–86. · DOI
  19. Chua, M.M.J., Lee, M., and Dominguez, I. (2017a). Cancer-type dependent expression of CK2 transcripts. PLoS One 12, e0188854. · DOI
  20. Chua, M.M.J., Ortega, C.E., Sheikh, A., Lee, M., Abdul-Rassoul, H., Hartshorn, K.L., and Dominguez, I. (2017b). CK2 in cancer: cellular and biochemical mechanisms and potential therapeutic target. Pharmaceuticals 10, 18. · DOI
  21. Cullere, X., Rose, P., Thathamangalam, U., Chatterjee, A., Mullane, K.P., Pallas, D.C., Benjamin, T.L., Roberts, T.M., and Schaffhausen, B.S. (1998). Serine 257 phosphorylation regulates association of polyomavirus middle T antigen with 14-3-3 proteins. J. Virol. 72, 558–563. · DOI
  22. Del Nonno, F., Pisani, G., Visca, P., Signore, F., Grillo, L.R., Baiocchini, A., Garbuglia, A.R., Sepe, S., Piacentini, M., and Falasca, L. (2011). Role and predictive strength of transglutaminase type 2 expression in premalignant lesions of the cervix. Modern Pathol. 24, 855. · DOI
  23. Delury, C.P., Marsh, E.K., James, C.D., Boon, S.S., Banks, L., Knight, G.L., and Roberts, S. (2013). The role of protein kinase A regulation of the E6 PDZ-binding domain during the differentiation-dependent life cycle of human papillomavirus type 18. J. Virol. 87, 9463–9472. · DOI
  24. Dick, F.A. and Dyson, N.J. (2002). Three regions of the pRB pocket domain affect its inactivation by human papillomavirus E7 proteins. J. Virol. 76, 6224–6234. · DOI
  25. Doorbar, J., Quint, W., Banks, L., Bravo, I.G., Stoler, M., Broker, T.R., and Stanley, M.A. (2012). The biology and life-cycle of human papillomaviruses. Vaccine 30 (Suppl 5), F55–70. · DOI
  26. Dyson, N., Howley, P.M., Munger, K., and Harlow, E. (1989). The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243, 934–937. · DOI · Paper page
  27. Engelke, C.G., Parsels, L.A., Qian, Y., Zhang, Q., Karnak, D., Robertson, J.R., Tanska, D.M., Wei, D., Davis, M.A., Parsels, J.D., et al. (2013). Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Clin. Cancer Res. 19, 4412–4421. · DOI
  28. Findik, D., Song, Q., Hidaka, H., and Lavin, M. (1995). Protein kinase A inhibitors enhance radiation-induced apoptosis. J. Cell Biochem. 57, 12–21. · DOI
  29. Firzlaff, J.M., Luscher, B., and Eisenman, R.N. (1991). Negative charge at the casein kinase II phosphorylation site is important for transformation but not for Rb protein binding by the E7 protein of human papillomavirus type 16. Proc. Natl. Acad. Sci. USA 88, 5187–5191. · DOI
  30. Forman, D., de Martel, C., Lacey, C.J., Soerjomataram, I., Lortet-Tieulent, J., Bruni, L., Vignat, J., Ferlay, J., Bray, F., Plummer, M., et al. (2012). Global burden of human papillomavirus and related diseases. Vaccine 30 (Suppl 5), F12–23. · DOI
  31. Gao, Q., Kumar, A., Srinivasan, S., Singh, L., Mukai, H., Ono, Y., Wazer, D.E., and Band, V. (2000). PKN binds and phosphorylates human papillomavirus E6 oncoprotein. J. Biol. Chem. 275, 14824–14830. · DOI
  32. Garcia-Alai, M.M., Alonso, L.G., and de Prat-Gay, G. (2007). The N-terminal module of HPV16 E7 is an intrinsically disordered domain that confers conformational and recognition plasticity to the oncoprotein. Biochemistry 46, 10405–10412. · DOI
  33. Genovese, N.J., Banerjee, N.S., Broker, T.R., and Chow, L.T. (2008). Casein kinase II motif-dependent phosphorylation of human papillomavirus E7 protein promotes p130 degradation and S-phase induction in differentiated human keratinocytes. J. Virol. 82, 4862–4873. · DOI
  34. Genovese, N.J., Broker, T.R., and Chow, L.T. (2011). Nonconserved lysine residues attenuate the biological function of the low-risk human papillomavirus E7 protein. J. Virol. 85, 5546–5554. · DOI
  35. Heck, D.V., Yee, C.L., Howley, P.M., and Munger, K. (1992). Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc. Natl. Acad. Sci. USA 89, 4442–4446. · DOI
  36. Hong, H.Y., Jeon, W.K., Bae, E.J., Kim, S.T., Lee, H.J., Kim, S.J., and Kim, B.C. (2010). 14-3-3 sigma and 14-3-3 zeta plays an opposite role in cell growth inhibition mediated by transforming growth factor-β1. Mol. Cells. 29, 305–309. · DOI
  37. Huibregtse, J.M., Scheffner, M., and Howley, P.M. (1993). Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol. Cell Biol. 13, 4918–4927. · DOI · Paper page
  38. James, C.D. and Roberts, S. (2016). Viral interactions with PDZ domain-containing proteins-an oncogenic trait? Pathogens. 5, pii: E8. doi: 10.3390. · DOI · Paper page
  39. Jensen, T.J., Loo, M.A., Pind, S., Williams, D.B., Goldberg, A.L., and Riordan, J.R. (1995). Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83, 129–135. · DOI
  40. Jeon, J.H., Choi, K.H., Cho, S.Y., Kim, C.W., Shin, D.M., Kwon, J.C., Song, K.Y., Park, S.C., and Kim, I.G. (2003). Transglutaminase 2 inhibits Rb binding of human papillomavirus E7 by incorporating polyamine. EMBO J. 22, 5273–5282. · DOI
  41. Jeon, J.H., Cho, S.Y., Kim, C.W., Shin, D.M., Jang, G.Y., Lee, H.J., Kang, H.S., Park, S.C., and Kim, I.G. (2006). Alteration of Rb binding to HPV 18 E7 modified by transglutaminase 2 with different type of polyamines. Front Biosci. 11, 1540–1548. · DOI
  42. Jones, D.L., Thompson, D.A., and Munger, K. (1997). Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 239, 97–107. · DOI · Paper page
  43. Kamio, M., Yoshida, T., Ogata, H., Douchi, T., Nagata, Y., Inoue, M., Hasegawa, M., Yonemitsu, Y., and Yoshimura, A. (2004). SOCS1 [corrected] inhibits HPV-E7-mediated transformation by inducing degradation of E7 protein. Oncogene 23, 3107–3115. · DOI
  44. Kao, W.H., Beaudenon, S.L., Talis, A.L., Huibregtse, J.M., and Howley, P.M. (2000). Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase. J. Virol. 74, 6408–6417. · DOI
  45. Kehmeier, E., Ruhl, H., Voland, B., Stoppler, M.C., Androphy, E., and Stoppler, H. (2002). Cellular steady-state levels of “high risk” but not “low risk” human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities. Virology 299, 72–87. · DOI
  46. Kuhne, C., Gardiol, D., Guarnaccia, C., Amenitsch, H., and Banks, L. (2000). Differential regulation of human papillomavirus E6 by protein kinase A: conditional degradation of human discs large protein by oncogenic E6. Oncogene 19, 5884–5891. · DOI
  47. Kukic, P., Lo Piccolo, G.M., Nogueira, M.O., Svergun, D.I., Vendruscolo, M., Felli, I.C., and Pierattelli, R. (2019). The free energy landscape of the oncogene protein E7 of human papillomavirus type 16 reveals a complex interplay between ordered and disordered regions. Sci. Rep. 9, 5822. · DOI
  48. Lee, J.O., Russo, A.A., and Pavletich, N.P. (1998). Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 391, 859–865. · DOI
  49. Liang, Y.J., Chang, H.S., Wang, C.Y., and Yu, W.C. (2008). DYRK1A stabilizes HPV16E7 oncoprotein through phosphorylation of the threonine 5 and threonine 7 residues. Int. J. Biochem. Cell Biol. 40, 2431–2441. · DOI
  50. Lin, W. and Chen, S. (2018). Checkpoint kinase 1 is overexpressed during HPV16-induced cervical carcinogenesis. Gynecol. Obstet. Invest. 83, 299–305. · DOI
  51. Lin, C.H., Chang, H.S., and Yu, W.C. (2008). USP11 stabilizes HPV-16E7 and further modulates the E7 biological activity. J. Biol. Chem. 283, 15681–15688. · DOI
  52. Litchfield, D.W. (2003). Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem. J. 369, 1–15. · DOI
  53. Liu, X., Clements, A., Zhao, K., and Marmorstein, R. (2006). Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J. Biol. Chem. 281, 578–586. · DOI
  54. Liu, J., Cao, X.C., Xiao, Q., and Quan, M.F. (2015). Apigenin inhibits HeLa sphere-forming cells through inactivation of casein kinase 2alpha. Mol. Med. Rep. 11, 665–669. · DOI
  55. Lorand, L. and Graham, R.M. (2003). Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol. 4, 140–156. · DOI
  56. Manzo-Merino, J., Thomas, M., Fuentes-Gonzalez, A.M., Lizano, M., and Banks, L. (2013). HPV E6 oncoprotein as a potential therapeutic target in HPV related cancers. Expert Opin. Ther. Targets 17, 1357–1368. · DOI
  57. Marin, O., Meggio, F., Marchiori, F., Borin, G., and Pinna, L.A. (1986). Site specificity of casein kinase-2 (TS) from rat liver cytosol. A study with model peptide substrates. Eur. J. Biochem. 160, 239–244. · DOI
  58. Marin, O., Meggio, F., and Pinna, L.A. (1994). Design and synthesis of two new peptide substrates for the specific and sensitive monitoring of casein kinases-1 and -2. Biochem. Biophys. Res. Commun. 198, 898–905. · DOI
  59. Massimi, P. and Banks, L. (1997). Repression of p53 transcriptional activity by the HPV E7 proteins. Virology 227, 255–259. · DOI
  60. Massimi, P. and Banks, L. (2000). Differential phosphorylation of the HPV-16 E7 oncoprotein during the cell cycle. Virology. 276, 388–394. · DOI
  61. Mehanna, H., Beech, T., Nicholson, T., El-Hariry, I., McConkey, C., Paleri, V., and Roberts, S. (2013). Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer – systematic review and meta-analysis of trends by time and region. Head Neck 35, 747–755. · DOI · Paper page
  62. Montagnoli, A., Fiore, F., Eytan, E., Carrano, A.C., Draetta, G.F., Hershko, A., and Pagano, M. (1999). Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev. 13, 1181–1189. · DOI
  63. Montano, R., Chung, I., Garner, K.M., Parry, D., and Eastman, A. (2012). Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol. Cancer Ther. 11, 427–438. · DOI
  64. Murao, S., Collart, F.R., and Huberman, E. (1989). A protein containing the cystic fibrosis antigen is an inhibitor of protein kinases. J. Biol. Chem. 264, 8356–8360. · DOI
  65. Muslin, A.J., Tanner, J.W., Allen, P.M., and Shaw, A.S. (1996). Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84, 889–897. · DOI
  66. Myung, J., Kim, K.B., and Crews, C.M. (2001). The ubiquitin-proteasome pathway and proteasome inhibitors. Med. Res. Rev. 21, 245–273. · DOI
  67. Neal, C.L. and Yu, D. (2010). 14-3-3zeta as a prognostic marker and therapeutic target for cancer. Expert. Opin. Ther. Targets 14, 1343–1354. · DOI
  68. Nogueira, M.O., Hosek, T., Calcada, E.O., Castiglia, F., Massimi, P., Banks, L., Felli, I.C., and Pierattelli, R. (2017). Monitoring HPV-16 E7 phosphorylation events. Virology 503, 70–75. · DOI
  69. Oh, K.J., Kalinina, A., Wang, J., Nakayama, K., Nakayama, K.I., and Bagchi, S. (2004). The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase. J. Virol. 78, 5338–5346. · DOI
  70. Ohlenschlager, O., Seiboth, T., Zengerling, H., Briese, L., Marchanka, A., Ramachandran, R., Baum, M., Korbas, M., Meyer-Klaucke, W., Durst, M., et al. (2006). Solution structure of the partially folded high-risk human papilloma virus 45 oncoprotein E7. Oncogene 25, 5953–5959. · DOI
  71. Ortega, C.E., Seidner, Y., and Dominguez, I. (2014). Mining CK2 in cancer. PLoS One 9, e115609. · DOI
  72. Pagano, M.A., Meggio, F., Ruzzene, M., Andrzejewska, M., Kazimierczuk, Z., and Pinna, L.A. (2004). 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem. Biophys. Res. Commun. 321, 1040–1044. · DOI
  73. Palmer, R.H., Ridden, J., and Parker, P.J. (1995). Cloning and expression patterns of two members of a novel protein-kinase-C-related kinase family. Eur. J. Biochem. 227, 344–351. · DOI
  74. Perea, S.E., Reyes, O., Puchades, Y., Mendoza, O., Vispo, N.S., Torrens, I., Santos, A., Silva, R., Acevedo, B., Lopez, E., et al. (2004). Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). Cancer Res. 64, 7127–7129. · DOI
  75. Perea, Y., Farina, H.G., Hernandez, I., Mendoza, O., Serrano, J.M., Reyes, O., Gomez, D.E., Gomez, R.E., Acevedo, B.E., Alonso, D.F., et al. (2008a). Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice. Int. J. Cancer 122, 57–62. · DOI
  76. Perea, S.E., Reyes, O., Baladron, I., Perera, Y., Farina, H., Gil, J., Rodriguez, A., Bacardi, D., Marcelo, J.L., Cosme, K., et al. (2008b). CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo. Mol. Cell Biochem. 316, 163–167. · DOI
  77. Perea, S.E., Baladron, I., Valenzuela, C., and Perera, Y. (2018). CIGB-300: a peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation. Semin. Oncol. 45, 58–67. · DOI
  78. Phillips, A.C. and Vousden, K.H. (1997). Analysis of the interaction between human papillomavirus type 16 E7 and the TATA-binding protein, TBP. J. Gen. Virol. 78, 905–909. · DOI
  79. Pierre, F., Chua, P.C., O’Brien, S.E., Siddiqui-Jain, A., Bourbon, P., Haddach, M., Michaux, J., Nagasawa, J., Schwaebe, M.K., Stefan, E., et al. (2011). Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J. Med. Chem. 54, 635–654. · DOI
  80. Piirsoo, A., Piirsoo, M., Kala, M., Sankovski, E., Lototskaja, E., Levin, V., Salvi, M., and Ustav, M. (2019). Activity of CK2α protein kinase is required for efficient replication of some HPV types. PLoS Pathog. 15, e1007788. · DOI
  81. Prives, C. (1990). The replication functions of SV40 T antigen are regulated by phosphorylation. Cell 61, 735–738. · DOI
  82. Propper, D.J., Saunders, M.P., Salisbury, A.J., Long, L., O’Byrne, K.J., Braybrooke, J.P., Dowsett, M., Taylor, M., Talbot, D.C., Ganesan, T.S., et al. (1999). Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects. Clin. Cancer Res. 5, 1682–1689.
  83. Rabalski, A.J., Gyenis, L., and Litchfield, D.W. (2016). Molecular pathways: emergence of protein kinase CK2 (CSNK2) as a potential target to inhibit survival and DNA damage response and repair pathways in cancer cells. Clin. Cancer Res. 22, 2840–2847. · DOI
  84. Reinstein, E., Scheffner, M., Oren, M., Ciechanover, A., and Schwartz, A. (2000). Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene 19, 5944–5950. · DOI
  85. Rey, O., Lee, S., Baluda, M.A., Swee, J., Ackerson, B., Chiu, R., and Park, N.H. (2000). The E7 oncoprotein of human papillomavirus type 16 interacts with F-actin in vitro and in vivo. Virology 268, 372–381. · DOI
  86. Roden, R.B.S. and Stern, P.L. (2018). Opportunities and challenges for human papillomavirus vaccination in cancer. Nat. Rev. Cancer 18, 240–254. · DOI
  87. Roman, A. and Munger, K. (2013). The papillomavirus E7 proteins. Virology 445, 138–168. · DOI
  88. Sarabia-Vega, V. and Banks, L. (2019). Acquisition of a phospho-acceptor site enhances HPV E6 PDZ-binding motif functional promiscuity. J. Gen. Virol., doi: 10.1099/jgv.0.001236. [Epub ahead of print]. · DOI
  89. Sarno, S., Vaglio, P., Meggio, F., Issinger, O.G., and Pinna, L.A. (1996). Protein kinase CK2 mutants defective in substrate recognition. Purification and kinetic analysis. J. Biol. Chem. 271, 10595–10601. · DOI
  90. Scheffner, M., Werness, B.A., Huibregtse, J.M., Levine, A.J., and Howley, P.M. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129–1136. · DOI · Paper page
  91. Schiffman, M., Doorbar, J., Wentzensen, N., de Sanjose, S., Fakhry, C., Monk, B.J., Stanley, M.A., and Franceschi, S. (2016). Carcinogenic human papillomavirus infection. Nat. Rev. Dis. Primers. 2, 16086. · DOI · Paper page
  92. Schwede, F., Maronde, E., Genieser, H., and Jastorff, B. (2000). Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacol. Ther. 87, 199–226. · DOI
  93. Selvey, L.A., Dunn, L.A., Tindle, R.W., Park, D.S., and Frazer, I.H. (1994). Human papillomavirus (HPV) type 18 E7 protein is a short-lived steroid-inducible phosphoprotein in HPV-transformed cell lines. J. Gen. Virol. 75, 1647–1653. · DOI
  94. Serrano, B., Brotons, M., Bosch, F.X., and Bruni, L. (2018). Epidemiology and burden of HPV-related disease. Best Pract. Res. Clin. Obstet. Gynaecol. 47, 14–26. · DOI
  95. Siddiqui-Jain, A., Drygin, D., Streiner, N., Chua, P., Pierre, F., O’Brien, S.E., Bliesath, J., Omori, M., Huser, N., Ho, C., et al. (2010). CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 70, 10288–10298. · DOI
  96. Singh, M., Krajewski, M., Mikolajka, A., and Holak, T.A. (2005). Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequences. J. Biol. Chem. 280, 37868–37876. · DOI
  97. Smotkin, D. and Wettstein, F.O. (1987). The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein. J. Virol. 61, 1686–1689. · DOI · Paper page
  98. Solares, A.M., Santana, A., Baladron, I., Valenzuela, C., Gonzalez, C.A., Diaz, A., Castillo, D., Ramos, T., Gomez, R., Alonso, D.F., et al. (2009). Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. BMC Cancer 9, 146. · DOI
  99. Southern, S.A., Lewis, M.H., and Herrington, C.S. (2004). Induction of tetrasomy by human papillomavirus type 16 E7 protein is independent of pRb binding and disruption of differentiation. Br. J. Cancer 90, 1949–1954. · DOI
  100. Thatte, J., Massimi, P., Thomas, M., Boon, S.S., and Banks, L. (2018). The HPV E6 PDZ binding motif links DNA damage response signaling to E6 inhibition of p53 transcriptional activity. J. Virol. 92, e00465–18. · DOI
  101. Thomas, M. and Banks, L. (1998). Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 17, 2943–2954. · DOI · Paper page
  102. Thomas, M. and Banks, L. (1999). Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J. Gen. Virol. 80, 1513–1517. · DOI · Paper page
  103. Thomas, M., Massimi, P., Navarro, C., Borg, J.P., and Banks, L. (2005). The hScrib/Dlg apico-basal control complex is differentially targeted by HPV-16 and HPV-18 E6 proteins. Oncogene 24, 6222–6230. · DOI · Paper page
  104. Thomas, M., Myers, M.P., Massimi, P., Guarnaccia, C., and Banks, L. (2016). Analysis of multiple HPV E6 PDZ interactions defines type-specific PDZ fingerprints that predict oncogenic potential. PLoS Pathog. 12, e1005766. · DOI · Paper page
  105. Tomaic, V. (2016). Functional roles of E6 and E7 oncoproteins in HPV-induced malignancies at diverse anatomical sites. Cancers (Basel) 8, pii: E95. · DOI
  106. Tomaic, V., Pim, D., and Banks, L. (2009). The stability of the human papillomavirus E6 oncoprotein is E6AP dependent. Virology 393, 7–10. · DOI · Paper page
  107. Tortora, G. and Ciardiello, F. (2002a). Protein kinase A as target for novel integrated strategies of cancer therapy. Ann. N.Y. Acad. Sci. 968, 139–147. · DOI
  108. Tortora, G. and Ciardiello, F. (2003). Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy. Ann. N.Y. Acad. Sci. 1002, 236–243. · DOI
  109. Tugizov, S., Berline, J., Herrera, R., Penaranda, M.E., Nakagawa, M., and Palefsky, J. (2005). Inhibition of human papillomavirus type 16 E7 phosphorylation by the S100 MRP-8/14 protein complex. J. Virol. 79, 1099–1112. · DOI
  110. Vande Pol, S.B. and Klingelhutz, A.J. (2013). Papillomavirus E6 oncoproteins. Virology 445, 115–137. · DOI
  111. Vos, R.M., Altreuter, J., White, E.A., and Howley, P.M. (2009). The ubiquitin-specific peptidase USP15 regulates human papillomavirus type 16 E6 protein stability. J. Virol. 83, 8885–8892. · DOI
  112. Wang, J., Sampath, A., Raychaudhuri, P., and Bagchi, S. (2001). Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells. Oncogene 20, 4740–4749. · DOI
  113. Watson, R.A., Thomas, M., Banks, L., and Roberts, S. (2003). Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes. J. Cell Sci. 116, 4925–4934. · DOI
  114. Yamato, K., Yamada, T., Kizaki, M., Ui-Tei, K., Natori, Y., Fujino, M., Nishihara, T., Ikeda, Y., Nasu, Y., Saigo, K., et al. (2008). New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer Gene Ther. 15, 140–153. · DOI · Paper page
  115. Yang, S.H., Kuo, T.C., Wu, H., Guo, J.C., Hsu, C., Hsu, C.H., Tien, Y.W., Yeh, K.H., Cheng, A.L., and Kuo, S.H. (2016). Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer. World J. Gastroenterol. 22, 7275–7288. · DOI
  116. Yoshinouchi, M., Yamada, T., Kizaki, M., Fen, J., Koseki, T., Ikeda, Y., Nishihara, T., and Yamato, K. (2003). In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol. Ther. 8, 762–768. · DOI · Paper page
  117. Zhang, J.G., Farley, A., Nicholson, S.E., Willson, T.A., Zugaro, L.M., Simpson, R.J., Moritz, R.L., Cary, D., Richardson, R., Hausmann, G., et al. (1999). The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. USA 96, 2071–2076. · DOI
  118. Zhang, Y., Dasgupta, J., Ma, R.Z., Banks, L., Thomas, M., and Chen, X.S. (2007). Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein. J. Virol. 81, 3618–3626. · DOI
  119. Zine El Abidine, A., Tomaic, V., Bel Haj Rhouma, R., Massimi, P., Guizani, I., Boubaker, S., Ennaifer, E., and Banks, L. (2017). A naturally occurring variant of HPV-16 E7 exerts increased transforming activity through acquisition of an additional phospho-acceptor site. Virology 500, 218–225. · DOI

Cited by

See all 19

Metadata

Authors
Basukala, O., Sarabia-Vega, V., & Banks, L.
Affiliations
International Centre for Genetic Engineering and Biotechnology , AREA Science Park, Padriciano 99, I-34149 Trieste , Italy
ORCID
Venue
Biological Chemistry
Publisher
Walter de Gruyter GmbH
Published
2020-01-08
Volume
401
Issue
5
Pages
585-599
ISSN
  • 1437-4315
  • 1431-6730
DOI
10.1515/hsz-2019-0408
Cited by
19
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review